Oral Anti Diabetic Drug Market Research Report till 2025 with Trends and Forecast

1
GLOBAL MARKET ESTIMATES RESEARCH
CONSULTANTS Ankita Roy, Treesha Banerjee and
Liza Dsouza from Global Market Estimates throw
the spotlight on the growing Global Oral Anti
Diabetic Drug Market. Oral Anti Diabetic Drug
Market Insights The oral antidiabetic drug
market is projected to grow at a high CAGR over
the coming years. Rising prevalence of diabetes
across the world coupled with growing
pharmaceutical investments in developing
efficient and safe drugs that can be administered
easily is projected to boost demand for the oral
antidiabetic drug. Oral diabetic drugs help
reduce the absorption of glucose, therefore,
enabling cells to use glucose more effectively.
The introduction of financial and insurance
policies that addresses the requirements of
diabetic patients is anticipated to propel market
demand over the coming years.
Oral Anti Diabetic Drug Market Drug Insights On
the basis of the drug, the market is segmented
into Alpha-Glucosidase inhibitors, Biguanide,
Sodium - glucose cotransport -2 (SGLT-2)
inhibitor, Dopamine -D2 receptor agonist,
Dipeptidyl peptidase - 4 (DPP-4) inhibitors,
Meglitinide, and Sulfonylureas. Dipeptidyl
peptidase - 4 (DPP-4) inhibitors were estimated
to observe the largest demand in 2017. This drug
helps lower glucose levels for management of type
2 diabetes. The requirement for drugs that offer
minimal side effects, safe usage, and convenient
dosage regimen are projected to stay in demand
over the coming years.
2
GLOBAL MARKET ESTIMATES RESEARCH
CONSULTANTS Oral Anti Diabetic Drug Market
Regional Insights The North American region is
projected to hold the largest share in the
antidiabetic drug market. In July 2017, it was
estimated by the Centers for Disease Control and
Prevention (CDC) that more than 100 million
adults in the U.S. suffered from diabetics. The
increasing number of obese population and its
concurrent adverse impact leading to diabetes is
projected to increase demand for oral
drugs. The Asia Pacific region is projected to
grow at a high CAGR over the coming years,
followed by countries in the Middle East
Africa and Central South America. High
prevalence of diabetes in countries such as
Malaysia, Singapore, India, Sri Lanka, and China
among others is projected to augment demand for
the oral antidiabetic drug in the region.
Availability of these drugs at a cheaper rate in
countries such as China is also anticipated to
boost demand over the coming years.
Oral Anti Diabetic Drug Market End-Use
Landscape The end-use landscape entails a list
of current and prospective consumers prevailing
across the regions. This section provides
company addresses, contact details, products, and
regional presence of companies who are
purchasing or are likely to prescribe oral
antidiabetic drug over the coming years. Some
leading prescribers of this market are Mayo
Clinic, Cleveland Clinic, UCSF Medical Center,
Massachusetts General Hospital, and Johns Hopkins
Hospital among others.
3

• GLOBAL MARKET ESTIMATES RESEARCH CONSULTANTS
• Oral Anti Diabetic Drug Market Vendor Landscape
• The report contains a chapter dedicated to
  vendors operating in the market, covering raw
  material manufactures, equipment developers,
  manufacturers, and distributors. The report
  provides these insights on a regional level. This
  section of the report entails contact details,
  experience, products manufactured/supplied, and
  geographical presence of companies.
• Oral Anti Diabetic Drug Market Share Competitor
  Analysis
• Some of the key companies in the oral anti
  diabetic drug market are Takeda, Eli Lilly,
  Astellas, Pfizer, Merck And Co., Novartis,
  Sanofi, Bristol Myers Squibb, AstraZeneca,
  Boehringer Ingelheim, Johnson Johnson, and
  Janssen Pharmaceuticals among others.
• In December 2017, Pfizer and Merck And Co.
  developed a new drug for type II diabetes which
  gained the approval of the Food and Drug
  Administration (FDA). The companys are
  anticipated to sell the drug under the brand name
  Steglatro.
• The report segments the Oral Anti Diabetic Drug
  Market on the basis of
• By Drug
• Biguanide
• Alpha Glucosidase inhibitors
• Dopamine -D2 receptor agonist

4
GLOBAL MARKET ESTIMATES RESEARCH CONSULTANTS
This article contains text from the Oral Anti
Diabetic Drug Market Forecast to 2025 report
prepared by Global Market Estimates. For more
information or to buy the report, please visit
https//www.globalmarketestimates.com/oral-antidia
betic-drug-market/ Check our annual research
partnership service at https//www.globalmarketes
timates.com/annual-research-partnership-services/